Table 1.
Clinical characteristics of patients with infliximab or adalimumab‐associated delayed cutaneous hypersensitivity in patients with COVID‐19 collected from the FAERS database.
| Reports (N, %) | ||
|---|---|---|
| Characteristics | Infliximab | Adalimumab |
| Patient age (year) | ||
| <18 | 0 (0.00) | 0 (0.00) |
| 18–44 | 0 (0.00) | 37 (8.02) |
| 45–64 | 0 (0.00) | 110 (23.86) |
| 65–74 | 1 (7.14) | 98 (21.26) |
| 75–84 | 0 (0.00) | 21 (4.56) |
| ≥85 | 0 (0.00) | 3 (0.65) |
| Unknown | 13 (92.86) | 192 (41.65) |
| Patient gender | ||
| Female | 2 (14.29) | 297 (64.43) |
| Male | 1 (7.14) | 162 (35.14) |
| Unknown | 11 (78.57) | 2 (0.43) |
| Year | ||
| 2020 | 0 (0.00) | 0 (0.00) |
| 2021 | 14 (100.00) | 461 (100.00) |
| Area | ||
| Africa | 0 (0.00) | 0 (0.00) |
| Asian | 0 (0.00) | 0 (0.00) |
| Europe | 1 (7.14) | 1 (0.22) |
| North America | 13 (92.86) | 443 (96.10) |
| Oceania | 0 (0.00) | 0 (0.00) |
| South America | 0 (0.00) | 17 (3.69) |
| Unknown | 0 (0.00) | 0 (0.00) |
| Reporters | ||
| Consumer | 3 (21.43) | 445 (96.53) |
| Pharmacist | 0 (0.00) | 0 (0.00) |
| Physician | 2 (14.29) | 7 (1.52) |
| Unknown | 9 (64.29) | 9 (1.95) |
| Mean weight | ||
| Weight (kg) | 101.00 | 83.93 |
Abbreviations: COVID‐19, coronavirus disease 2019; FEARS, Food and Drug Administration's Adverse Event Reporting Systems.